Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Trifolium pratense-Derived Exosome Improved Serum Biochemical Parameters and Pancreatic Genes in STZ-Induced Diabetic Rats

Khazaei AH., Bozorgi A., Ghanbari E., Bozorgi M., Khazaei M.

Animal Study on Systemic / IV, published in Endocrinol Diabetes Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Endocrinol Diabetes Metab (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40887321
PMCID
PMC12399343
DOI
10.1002/edm2.70103
Citations
1

Abstract (original English)

Introduction Plant-derived exosomes (PDEs) are promising nanotherapeutics for improving chronic diseases, such as diabetes mellitus. Trifolium pratense (TP) is a flowering herb with potent antioxidant and antidiabetic properties. The present study aimed to explore the diabetic-healing effects of TP-derived exosomes (TPDEs) in streptozotocin (STZ)-induced diabetic rats. Methods TPDEs were isolated using polyethylene glycol precipitation and serial centrifugation and characterised. STZ-induced diabetic rats were treated with TPDE doses (0, 100, 200, and 400 μg/kg) for 28 days. Biochemical factors (fasting blood sugar (FBS), insulin, C-peptide, total antioxidant capacity (TAC), and nitric oxide (NO)) were evaluated in serum samples. Also, the expression of PDX1, insulin, NGN3, and SIRT1 genes in pancreas tissues was assessed using real-time PCR. Results TPDE treatment decreased the serum levels of FBS and NO while increasing c-peptide, insulin, and TAC levels. It also significantly enhanced the expression of insulin, PDX1, NGN3, and SIRT1 genes. TPDEs at doses of 100 to 200 μg/kg showed the most significant antidiabetic effects. Conclusion TPDEs significantly improved diabetes-induced alterations in serum insulin levels, antioxidant status, and pancreas-related gene expression. It can be considered a novel complementary treatment for diabetes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
PancreasAnimalsRatsRats, WistarTrifoliumDiabetes Mellitus, ExperimentalStreptozocinInsulinC-PeptideBlood Glucose

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research